



# GLOBAL ASSET ALLOCATION: THE VIEW FROM THE UK

February 2021

## MARKET INSIGHTS

As of 31 January 2021

### Mutating Expectations

Optimism surrounding the global economic recovery is beginning to change as potentially deadlier variants of the coronavirus found in the UK, Brazil and South Africa are spreading just as vaccine rollout efforts have gotten underway. The potentially more transmittable and harmful mutations have led to renewed lockdowns, particularly in the UK and eurozone, and are threatening to push some regions into double-dip recessions. Current vaccines such as the one produced by Moderna are reported to still be effective against the new variants, but the pressure is on nations around the world to advance vaccinations to control the virus as it has shown the ability to aggressively mutate. The concerning mutations come as many regions are facing vaccine shortages and challenges surrounding vaccine storage and distribution. The next few months will be a critical race against the virus, as the longer it takes to control, the more damage it will have on lives and expectations for a global recovery.

### Leaping Ahead


As the rest of the world struggles to get back on its feet, China reported that its economy grew 2.3% last year, making it the only major economy to report positive growth in 2020. After posting a strong 6.5% year-over-year growth rate in the fourth quarter, supported by investment spending and export growth, China's economy leapt back to pre-pandemic levels and made strides toward becoming the world's largest economy. China's V-shaped recovery can be attributed to the early, stringent lockdown measures put in place to control the spread of the virus and the deployment of significant fiscal and monetary stimulus. A focus on infrastructure and a surge in pandemic-related demand—from masks to home office equipment—helped propel export demand, while domestic consumption contracted by 3.9% as retail sales remain one of the hardest-hit sectors amid the pandemic. China has worked for years to reduce its dependence on trade and grow domestic consumption, so the setback is likely to be temporary.

### Off to a Quick Start

While the Biden administration put eradicating the coronavirus at the top of its agenda, taking action on regulations with executive orders has also been a top priority. Deregulation was a defining focus of the prior administration, notably within the energy sector; however, Biden has rapidly revisited a wide range of regulations emphasising climate change and green energy, as well as equality. On his first day, Biden temporarily suspended new permits for oil and gas leases on US properties, shut down the Keystone XL pipeline, and rejoined the Paris Climate Agreement. Democrats in Congress have also been swift to act on their agenda, pushing an additional USD 1.9 trillion stimulus package, on top of last year's USD 4 trillion, and may look to use reconciliation, allowing for a simple majority in the Senate, to avoid requirements for a 60-vote threshold. While still early in the new government, Democrats are acting quickly and independently on advancing their agenda—perhaps more than the market may have anticipated when it expected a divided government.


### US Hospitalisations and Cumulative Vaccinations

As of 31 January 2021




### Nominal GDP by Country (in trillions)<sup>1</sup>

As of 31 December 2020



### US Federal Government Budget Surplus/Deficit (as % of GDP)

As of 31 December 2020



<sup>1</sup> These figures are in USD and annualised.

Sources: CDC, Covid Tracking Project (covidtracking.com), Bureau of Economic Analysis/Haver Analytics, US Treasury/Haver Analytics.



 **Positives**

 **Negatives**

**United Kingdom**

- Rapid vaccination means that the economy could return closer to normal by the autumn, potentially three or four months ahead of eurozone countries
- Fiscal support for firms and workers continues to be extended during the second wave
- The prospect of negative rates has been pushed back by at least six months
- A Brexit deal has been achieved

- New coronavirus variant means a tougher national lockdown in January and February
- Brexit transition and third lockdown could mean the second quarterly gross domestic product (GDP) contraction in a row
- Demand risks from housing market weakness and large fiscal consolidation remain
- Bank of England's forecasts suggest optimism and less easing, but given large risks to demand, negative risks may still materialise within the next year

**Developed Europe**

- Higher exposure to more cyclically oriented sectors that should benefit from economic recovery
- Monetary and fiscal policy remain accommodative
- Equity valuations remain attractive
- Stronger long-term euro outlook

- New lockdowns amid second wave of virus
- Vaccination effort facing supply shortages
- Brexit likely to negatively impact trade
- Limited scope for European Central Bank (ECB) to stimulate further
- Limited long-term catalysts for growth


**United States**

- Stronger probability for more fiscal support
- Vaccination rollout underway
- Monetary policy remains very accommodative
- Healthy consumer balance sheets and high savings rate

- Elevated stock and bond valuations
- Corporate and government debt at high levels
- US dollar weakness continues
- Unemployment remains elevated

 **Positives** **Negatives**

- 
- |                              |   |  |
|------------------------------|---|--|
| <b>Japan</b>                 | <ul style="list-style-type: none"><li>▪ The economy continues to heal at a slow pace with an accommodative policy backdrop</li><li>▪ Domestic stocks are a global reflation play, with positive correlations to Purchasing Managers' Indices and bond yields</li><li>▪ While current recovery will be centered on traditional industries like automakers, Japan Inc. is changing with a push toward digitalisation and governance</li></ul>   | <ul style="list-style-type: none"><li>▪ Economic momentum remains fragile with manufacturing indicators still below pre-pandemic levels</li><li>▪ The pandemic is not yet under control during this winter season and vaccine rollout is not expected until late February</li><li>▪ Market indicators signal a stronger yen, which would reduce companies' competitiveness and profitability</li></ul>   |
| <b>Asia Pacific ex-Japan</b> | <ul style="list-style-type: none"><li>▪ Chinese economic growth is solid, supported by strong exports and the potential for domestic consumption to follow through</li><li>▪ Demand for Chinese assets is expected to attract significant inflows, adding pressure to the yuan and bond yields</li><li>▪ Strong consumer spending in Australia should continue, based on pent-up demand, an improving job market and extra savings</li><li>▪ The Australian economy surprise index is at record-high levels, boding well for near-term momentum</li></ul> | <ul style="list-style-type: none"><li>▪ Chinese economic momentum seems to be peaking while a tightening of policies is possible in the second half</li><li>▪ Tech dominance in the Chinese equity markets may be a headwind in the face of new regulations and high valuations</li><li>▪ Risk exists that Australian support measures could be wound down too quickly, creating a hangover effect if the fiscal tap is turned off</li><li>▪ A strong Australian dollar might be the target of future measures from the central bank</li></ul> |
| <b>Emerging Markets</b>      | <ul style="list-style-type: none"><li>▪ Exposure to cyclical areas of the economy should benefit from broad global recovery</li><li>▪ Chinese economy remains strong</li><li>▪ US dollar weakness continues</li><li>▪ Equity valuations attractive relative to developed markets</li></ul>  | <ul style="list-style-type: none"><li>▪ Stimulus from China likely to fade going forward</li><li>▪ Limited ability to enact fiscal stimulus (excluding China)</li><li>▪ Vaccine supply and distribution infrastructure are well behind developed markets</li></ul>   |
-



**Past performance is not a reliable indicator of future performance.**

\* Includes Australia



Past performance is not a reliable indicator of future performance.



## UK INVESTMENT COMMITTEE



**Quentin Fitzsimmons**  
Senior Portfolio Manager,  
Fixed Income Division



**Andrew Keirle**  
Portfolio Manager, Emerging  
Markets Local Currency Bonds



**Yoram Lustig**  
Head of Multi-Asset  
Solutions, EMEA



**Ken Orchard**  
Senior Portfolio Manager,  
Fixed Income Division



**David Stanley**  
Portfolio Manager,  
European Corporate Bonds



**Toby Thompson**  
Portfolio Manager,  
Multi-Asset Division



**Mitchell Todd**  
Co-head of EMEA Equity



**Michael Walsh**  
Solutions Strategist, EMEA



**Tomasz Wieladek**  
International Economist

The specific securities identified and described are for informational purposes only and do not represent recommendations.

## INVEST WITH CONFIDENCE<sup>SM</sup>

T. Rowe Price focuses on delivering investment management excellence that investors can rely on—now and over the long term.

# T.RowePrice<sup>®</sup>

### Important Information

**This material is being furnished for general informational and/or marketing purposes only.** The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.

It is not intended for distribution to retail investors in any jurisdiction.

**DIFC**—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd. This material is communicated on behalf of T. Rowe Price International Ltd. by its representative office which is regulated by the Dubai Financial Services Authority. For Professional Clients only.

**EEA ex-UK**—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

**Switzerland**—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

**UK**—This material is issued and approved by T. Rowe Price International Ltd, 60 Queen Victoria Street, London, EC4N 4TZ which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

© 2021 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the bighorn sheep design are, collectively and/or apart, trademarks or registered trademarks of T. Rowe Price Group, Inc.